<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589471</url>
  </required_header>
  <id_info>
    <org_study_id>CE 11.088</org_study_id>
    <nct_id>NCT01589471</nct_id>
  </id_info>
  <brief_title>The Value of Botox-A for Management of Low Anterior Resection Syndrome</brief_title>
  <official_title>The Value of Botox-A Administered as a Single Intra-rectal Injection for the Management of Low Anterior Resection Syndrome: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low anterior resection syndrome (LARS) is frequent after treatment for low rectal cancer.&#xD;
      Increased bowel frequency and urgency with rectal spasms and incontinence have deleterious&#xD;
      impacts on quality of life in a third of the cases.&#xD;
&#xD;
      One possible physiopathology hypothesis suggests an ongoing spastic process; different&#xD;
      mechanisms have been postulated. These include alteration of normal anorectal sensation with&#xD;
      loss of the recto-anal inhibitory reflex (RAIR), decreased rectal compliance and reduced&#xD;
      rectal capacity as well as sphincter damage secondary to preoperative chemoradiation therapy&#xD;
      or during surgery.&#xD;
&#xD;
      Current available treatments are often ineffective, highlighting the need for more successful&#xD;
      management. Botulinum toxin A (BTX-A) is a neurotoxin inhibiting acetylcholine release at the&#xD;
      neuromuscular junction. It is currently used for the treatment of various smooth muscle&#xD;
      spastic diseases.&#xD;
&#xD;
      The hypothesis of this study is that intra-rectal BTX-A injections could represent a medical&#xD;
      treatment alternative for LARS. The goal of this study is to document the effects of&#xD;
      intra-rectal BTX-A injections on sphincter function and quality of life of patients with&#xD;
      LARS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No more information desired&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of intra-rectal Botox-A injection on anorectal function as documented with a visual scale for tenesmus and completeness of stool evacuation</measure>
    <time_frame>1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of intra-rectal Botox-A injection on quality of life as documented with EORTC-QlQ standardized questionnaires</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>EORTC-QIQ is a quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of intra-rectal Botox-A injection as documented with a patient medicine calender</measure>
    <time_frame>1 month</time_frame>
    <description>patient-filled calender for usage of any medication intended for symptomatic treatment of LARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized anorectal manometry readings</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term efficacy of intra-rectal Botox-A injection on anorectal function as documented with Wexner score, EORTC-QLQ questionnaire and visual scale</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of intra-rectal Botox-A injections as documented with adverse events monitoring</measure>
    <time_frame>1 month, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Low Anterior Resection Syndrome</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Botox-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-rectal (or intra-colic) injection of 100 U of Botox-A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intra-rectal Botulinum toxin A injection</intervention_name>
    <description>intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis</description>
    <arm_group_label>Botox-A</arm_group_label>
    <other_name>Botox (Allergan)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Aptitude to sign informed consent&#xD;
&#xD;
          -  Diagnosis of low anterior resection syndrome (LARS) : More than 12 months after&#xD;
             sphincter-preserving surgery for treatment of locally advanced rectal cancer, Mild to&#xD;
             moderate underwear soiling, Baseline Wexner score ranging from 0-16 (moderate&#xD;
             symptoms, and Patient-reported imperious defecation or Patient-reported incomplete&#xD;
             stool evacuation&#xD;
&#xD;
          -  Digital rectal exam (by surgeon) demonstrating satisfying anorectal tonus considering&#xD;
             prior radical rectal surgery.&#xD;
&#xD;
          -  Willingness to complete questionnaires and manometric studies before and after Botox-A&#xD;
             administration&#xD;
&#xD;
          -  Prior failed medical treatment, at least one attempt (narcotics, loperamide,&#xD;
             cholestyramine, fibers)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to sign informed consent&#xD;
&#xD;
          -  Counter-indication to Botox-A administration : Allergy to Botox-A or its ingredients&#xD;
             (Clostridium botulinum type A neurotoxin complex, human albumin and sodium chloride,&#xD;
             Allergy to other forms of botulinum toxin (Dysport, Xeomin or Myobloc, Myasthenia&#xD;
             gravis, Eaton-Lambert syndrome, lateral amyotrophic sclerosis or any other&#xD;
             neurological disease which might interfere with neuromuscular function&#xD;
&#xD;
          -  Prior use of any form of botulinum toxin A, for any indication&#xD;
&#xD;
          -  Infection at proposed Botox-A injection site&#xD;
&#xD;
          -  Personal or family history of bleeding diathesis&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Severe incontinence (Wexner score ≥ 17 or daily use of diapers)&#xD;
&#xD;
          -  Patient taking anticoagulant. ASA ( acetylsalicylic acid) allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole S Richard, MD FCRSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low anterior resection syndrome</keyword>
  <keyword>Botulinum toxin A</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Incontinence</keyword>
  <keyword>Rectal cancer</keyword>
  <keyword>Anorectal manometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

